Home › NDC Lookup › J-codes › J2267
J2267

J2267 – Inj, mirikizumab-mrkz, 1 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 7 NDCs crosswalked per 1 MG $32.658/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J2267 summary

J2267 is a HCPCS Level II J-code used to bill mirikizumab-mrkz, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J2267: Omvoh Pen*, Omvoh

Code J2267 Billing unit 1 MG Payment limit $32.658/unit NDC-Crosswalk 7 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ2267
DescriptorInj, mirikizumab-mrkz, 1 mg
Billing unit1 MG
Payment limit / unit$32.658
Est. ASP / unit$30.809 est.
Mapped NDCs7
Data periodQ3 2026
Last updated2026-08-20

💊 About Mirikizumab-Mrkz DRUG GUIDE

Omvoh (mirikizumab-mrkz) is used to treat moderately to severely active ulcerative colitis in adults — a condition where the large intestine becomes chronically inflamed and ulcerated.

It is also used to treat moderately to severely active Crohn's disease in adults, another form of inflammatory bowel disease that can affect any part of the digestive tract.Both uses are specific to Omvoh administered by injection — first as intravenous (into the vein) infusions to start treatment, then as subcutaneous (under the skin) injections for ongoing maintenance.

Read the full Mirikizumab-Mrkz drug guide →
Clinical overview from our editorial drug guide for Mirikizumab-Mrkz. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$32.658
Est. ASP / unit
$30.809 est.
Est. after 2% sequester
$32.005
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J2267 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J2267 WITH EST. MEDICARE PAY

7 NDCs map to J2267. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($32.658/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00002-1442-11 Omvoh mirikizumab-mrkz 100 mg/mL INJECTION, SOLUTION Eli 1 SYRINGE in 1 CARTON (0002-1442-11) / 2... 100 mg/mL 200 $6,531.60 — ● Active CMS ASP
00002-3116-11 Omvoh mirikizumab-mrkz 100 mg/mL INJECTION, SOLUTION Eli 1 SYRINGE in 1 CARTON (0002-3116-11) / 2... 100 mg/mL 200 $6,531.60 — ● Active CMS ASP
00002-7575-01 Omvoh mirikizumab-mrkz 20 mg/mL INJECTION, SOLUTION Eli 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-7575... 20 mg/mL 300 $9,797.40 — ● Active CMS + PDAC
00002-7717-11 Omvoh mirikizumab-mrkz KIT Eli 1 KIT in 1 CARTON (0002-7717-11) * 1 mL... — 300 $9,797.40 — ● Active CMS ASP
00002-7722-11 Omvoh mirikizumab-mrkz KIT Eli 1 KIT in 1 CARTON (0002-7722-11) * 1 mL... — 300 $9,797.40 — ● Active CMS ASP
00002-8011-27 Omvoh mirikizumab-mrkz 100 mg/mL INJECTION, SOLUTION Eli 2 SYRINGE in 1 CARTON (0002-8011-27) / 1... 100 mg/mL 200 $6,531.60 — ● Active CMS + PDAC
00002-8870-27 Omvoh mirikizumab-mrkz 100 mg/mL INJECTION, SOLUTION Eli 2 SYRINGE in 1 CARTON (0002-8870-27) / 1... 100 mg/mL 200 $6,531.60 — ● Active CMS + PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$1.94M
Claims
90
Beneficiaries
48
Spend / beneficiary
$40,313.28
Spend / claim
$21,500.42
Trend by period
Where J2267 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #325 of 824
#320 PURAPLY XT 1 SQ CM** Q4197 $2.14M #321 BKEMV Q5152 $2.1M #322 GAMIFANT J9210 $2.03M #323 HYPERRAB 90375 $2M #324 ELITEK J2783 $1.99M #325 OMVOH PEN* J2267 $1.94M #326 BIZENGRI J9382 $1.93M #327 THERASKIN** Q4121 $1.88M #328 ADYNOVATE J7207 $1.87M #329 ELFABRIO J2508 $1.79M #330 NEUPOGEN J1442 $1.77M
Total claims — #640 of 824
#635 DIPYRIDAMOLE J1245 96 #636 PFIZER COVID (6M-4... 91318 95 #637 REBYOTA J1440 95 #638 DIHYDROERGOTAMINE ME... J1110 94 #639 ELFABRIO J2508 94 #640 OMVOH PEN* J2267 90 #641 BREYANZI Q2054 89 #642 BUTORPHANOL TARTRATE J0595 88 #643 CYTOGAM J0850 88 #644 SEVENFACT J7212 87 #645 GEMCITABINE HCL(J919... J9196 86

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $1.94M 48 90 $40,313.28 $21,500.42
2025 (Q1-Q4) $8.07M 135 373 $59,748.32 $21,624.73
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$6.28M
Medicare paid
$5.12M
Submitted services
185,734
Denial rate
25.7%
Allowed / service
$45.50
Submitted charges
$16.05M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

📊 What bills under J2267

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
mirikizumab-mrkz 6
NDC products by labeler
Eli Lilly and Company 6

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
7 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J2267 billing FAQ

What is HCPCS code J2267?
J2267 is a HCPCS Level II J-code used to bill Inj, mirikizumab-mrkz, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2267?
One unit of J2267 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J2267 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2267?
The Medicare Part B payment limit is $32.658 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $32.005 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2267?
7 NDCs currently map to J2267 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2267 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.